- Home
- TTE vs GILD Comparison
TTE vs GILD Comparison
Compare TTE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TTE | GILD |
|---|---|---|
| Founded | 1924 | 1987 |
| Country | France | United States |
| Employees | 100000 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6B | 184.4B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | TTE | GILD |
|---|---|---|
| Price | $89.01 | $137.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 18 |
| Target Price | $72.45 | ★ $146.50 |
| AVG Volume (30 Days) | 2.1M | ★ 5.1M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.31% | 2.39% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $10.35 | $4.69 |
| Revenue Next Year | $6.18 | $5.95 |
| P/E Ratio | ★ $12.60 | $20.26 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $52.78 | $95.30 |
| 52 Week High | $91.38 | $157.29 |
Technical Indicators
Market Signals| Indicator | TTE | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 76.48 | 36.22 |
| Support Level | $59.43 | $108.90 |
| Resistance Level | N/A | $149.38 |
| Average True Range (ATR) | 1.53 | 3.17 |
| MACD | 0.68 | -1.46 |
| Stochastic Oscillator | 83.97 | 7.92 |
Price Performance
Historical ComparisonAbout TTE TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.5 million barrels of liquids and 5.2 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 11.1 billion barrels of oil equivalent, 54% of which are liquids. During 2024, it had LNG sales of 39.8 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 26 gigawatts.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).